دورية أكاديمية
Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer
| العنوان: | Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer |
|---|---|
| المؤلفون: | Masatoshi Maki, Ryo Takada, Akihiko Taniguchi, Naoyuki Nomura, Seiichiro Kuramoto, Yuki Chiko, Toshiaki Okada, Seiji Saito, Koji Tamura |
| المصدر: | Journal of Pharmaceutical Health Care and Sciences, Vol 8, Iss 1, Pp 1-10 (2022) |
| بيانات النشر: | BMC, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Therapeutics. Pharmacology LCC:Pharmacy and materia medica |
| مصطلحات موضوعية: | COVID 2019, Immune checkpoint inhibitor, Lung cancer, Respiratory failure, C-reactive protein, Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441 |
| الوصف: | Abstract Background COVID-19 has become a significant health threat and a primary healthcare concern among the most vulnerable patients with cancer. Patients with COVID-19 who have lung cancer are at great risk and need careful monitoring if they are affected. This study aimed to investigate the clinical characteristics of COVID-19-positive patients with lung cancer and the risks associated with anticancer medication. Methods This study was a single-center, retrospective cohort study. Patients with lung cancer who presented with COVID-19 during hospitalization were divided into two groups: those who presented with respiratory failure and those who did not. The patient's background, clinical laboratory values, and anticancer drugs used for therapy were investigated to identify risk factors for respiratory failure. Results Thirty-one patients were included in the study; 18 (58.1%) were in the respiratory failure group and 13 (41.9%) were in the group without respiratory failure. In the respiratory failure group, there was a significant difference in using immune checkpoint inhibitor (ICI) use within 90 days (p = 0.025) and the level of C-reactive protein (CRP) level (p = 0.017). The analysis of the operating characteristic of the receiver revealed a cutoff value of 2.75 mg/dL for CRP (area under the curve = 0.744, sensitivity 0.611, specificity 0.923). Conclusions A history of ICI within 90 days and elevated CRP (≥ 2.75 mg/dL) levels are potential factors leading to respiratory failure in COVID-19-affected patients undergoing chemotherapy for lung cancer. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2055-0294 |
| Relation: | https://doaj.org/toc/2055-0294 |
| DOI: | 10.1186/s40780-022-00259-6 |
| URL الوصول: | https://doaj.org/article/04fdeab9db774fafa447bd5bbde9694a |
| رقم الأكسشن: | edsdoj.04fdeab9db774fafa447bd5bbde9694a |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 20550294 |
|---|---|
| DOI: | 10.1186/s40780-022-00259-6 |